Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422461 | 0.84 | STK17A (0.56) | STK17ASTK17B | |
| SCHEMBL1937548 | 0.83 | STK17A (0.54) | STK17ASTK17B | |
| SCHEMBL20652148 | 0.81 | STK17A (0.52) | STK17ASTK17B | |
| SCHEMBL1400319 | 0.81 | STK17A (0.56) | STK17ASTK17B | |
| SCHEMBL1937398 | 0.81 | STK17A (0.56) | STK17ASTK17B | |
| SCHEMBL3715848 | 0.79 | STK17A (0.61) | STK17ASTK17B | |
| SCHEMBL21352288 | 0.78 | STK17A (0.63) | STK17ASTK17B | |
| SCHEMBL28748621 | 0.78 | SYK (0.46) | STK17ASTK17B | |
| SCHEMBL28748604 | 0.78 | SYK (0.46) | STK17ASTK17B | |
| SCHEMBL28748662 | 0.78 | SYK (0.46) | STK17ASTK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-05-12 | — | — | US | disclosed |
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-09-19 | — | — | US | disclosed |
| WO-2018088749-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | 한국화학연구원 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | DTYMK, TGFB1, DCK | STK17A 1127/4885STK17B 1114/4885 |
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | TGFBR1, TGFBR2, TGFB1 | STK17A 885/4885STK17B 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.